Antiphospholipid antibodies in patients with lupus nephritis.
The aim of this study was to compare the prevalence of anticardiolipin antibodies with other types of antiphospholipid antibodies (aPL) (antiphosphatidylserine--aPS, antiphosphatidylinositol--aPI, antiphosphatidylethanolamine--aPE) in patients with lupus nephritis and to find if the examination of a panel of various aPL is valuable for further diagnosis of patients. Additionally we determined the levels of autoantibodies against beta2-glycoprotein I (beta2GPI) and oxidized low-density lipoprotein (anti-oxLDL) and also investigated the relationship between antibodies against beta2GPI and oxLDL, which were assessed by ELISA methods. Twenty-two patients with lupus nephritis were studied. The control group consisted of 62 healthy blood donors. A statistically significant higher occurrence of all aPLs in the patients with lupus nephritis in comparison to the control group was found. The prevalence of polyspecific antibodies, which reacted with at least two various phospholipids, was 82% in the group of SLE patients. Significantly higher levels of IgG anti-beta2GPI in the sera of SLE patients (p = 0.0003) was detected. The levels of anti-oxLDL in the sera of the patients group did not differ significantly from the control one. Some positive samples for anti-beta2GPI and negative for aCL or anti-oxLDL and vice versa were found. It ca be concluded that the production of aPL including anti-beta2GPI and anti-oxLDL in the lupus nephritis patients is higher in comparison with healthy blood donors. We assume that the estimation of various types of aPL may be important in the selection of the group patients with renal diseases. The synthesis of aPL can reflect the spreading of the autoimmune response for several antigens modified on the vessel wall.
Fialová
Lenka
L
Institute for Medical Biochemistry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Zima
Tomás
T
Tesar
Vladimír
V
Mikulíková
Ludmila
L
Malbohan
Ivan M
IM
Merta
Miroslav
M
Certíková
Vĕra
V
D017153:Antibodies, Anticardiolipin / Q000097:blood / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D006023:Glycoproteins / Q000097:blood / Q000276:immunology; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood / Q000276:immunology; D008181:Lupus Nephritis / Q000097:blood / Q000276:immunology*; D010714:Phosphatidylethanolamines / Q000097:blood / Q000276:immunology; D010716:Phosphatidylinositols / Q000097:blood / Q000276:immunology; D010718:Phosphatidylserines / Q000097:blood / Q000276:immunology; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies; D006023:Glycoproteins; D008077:Lipoproteins, LDL; D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D010718:Phosphatidylserines; D053482:beta 2-Glycoprotein I; C099252:oxidized low density lipoprotein